Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Oryzon Genomics‘ iadademstat, an investigational oral therapy for ... Read more
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose ... Read more
The first patient has received treatment in a first-in-human Phase 1 trial of NKX101, Nkarta‘s investigational cell therapy for the treatment ... Read more
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new ... Read more
Australian scientists have created a promising new vaccine candidate against cancers that express the Wilms’ tumor 1 (WT1) gene. These include cancers ... Read more
Pfizer announced that the European Commission has approved Daurismo (glasdegib) in combination with low-dose cytarabine to treat newly diagnosed acute myeloid ... Read more
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information ... Read more
